Literature DB >> 22028305

The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits.

Medhat W Shafaa1, Neveen M Sabra, Rehab A Fouad.   

Abstract

Increased intraocular pressure (IOP) is a significant risk factor for the development of glaucoma. Timolol maleate is a beta-adrenergic receptor blocking agent and it is used for the treatment of glaucoma in order to reduce the elevated IOP that is characteristic of this eye disease. Systemic toxicity from topical timolol occurs more frequently than local toxicity and can affect the pulmonary, cardiac and central nervous systems. The objective of the present study, therefore, was to formulate multilamellar vesicles (MLVs) liposomal preparations of timolol maleate using their advantage of being less toxic compared with non-liposome-based drugs to be applied topically and to evaluate the in vivo performance of the prepared liposomes to extend the time of reduced IOP of glaucomatous rabbit's eye measured using a standard Shiotz tonometer. The encapsulation efficiency of MLVs was measured using a spectrophotometric technique. Differential scanning calorimetry (DSC) was used to monitor the effects of timolol maleate in the absence and presence of cholesterol on liposome thermal behaviour. Positively charged MLVs of timolol in the presence of a lower amount of cholesterol (DPPC(7):Chol(2):Timolol(2):SA(1) molar ratio) were found to be superior compared with other formulations in extending the ocular hypotensive effect approximately for 1 week (160 h) which encourages its physiological effectiveness. The increase of the cholesterol molar ratio in the prepared liposomal formulations serves to decrease the permeability of the lipid bilayer that is manifested by a low rate of drug release, an increased percentage of entrapment efficiency and a consequently lower bioavailability.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22028305     DOI: 10.1002/bdd.778

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  6 in total

Review 1.  Recent patents on ophthalmic nanoformulations and therapeutic implications.

Authors:  Ann-Marie Ako-Adounvo; Ramesh C Nagarwal; Lais Oliveira; Sai H S Boddu; Xiang S Wang; Surajit Dey; Pradeep K Karla
Journal:  Recent Pat Drug Deliv Formul       Date:  2014

2.  DOC-LS, a new liposome for dermal delivery, and its endocytosis by HaCaT and CCC-ESF-1 cells.

Authors:  Yong-Tai Zhang; Kai Zhang; Zhe Li; Hong-Yu Zhang; Teng Guo; Yan-Yan Li; Ji-Hui Zhao; Nian-Ping Feng
Journal:  IET Nanobiotechnol       Date:  2018-12       Impact factor: 1.847

3.  Exploring a Novel Fasudil-Phospholipid Complex Formulated as Liposomal Thermosensitive in situ Gel for Glaucoma.

Authors:  Aya M Khallaf; Riham M El-Moslemany; Mahmoud F Ahmed; Mahmoud H Morsi; Nawal M Khalafallah
Journal:  Int J Nanomedicine       Date:  2022-01-11

4.  Interaction of Coenzyme Q10 with Liposomes and its Impact on Suppression of Selenite - Induced Experimental Cataract.

Authors:  Medhat Wahba Shafaa; Amany Hasan Elshazly; Amira Zaki Dakrory; Maha Reda Elsyed
Journal:  Adv Pharm Bull       Date:  2018-03-18

5.  A novel ion-exchange carrier based upon liposome-encapsulated montmorillonite for ophthalmic delivery of betaxolol hydrochloride.

Authors:  Yi Huang; Qi Tao; Dongzhi Hou; Sheng Hu; Shuangyan Tian; Yanzhong Chen; Ruyi Gui; Lingling Yang; Yao Wang
Journal:  Int J Nanomedicine       Date:  2017-03-02

Review 6.  Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review.

Authors:  Marcelo Luís Occhiutto; Raul C Maranhão; Vital Paulino Costa; Anastasios G Konstas
Journal:  Adv Ther       Date:  2019-12-10       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.